Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy by Kunpeng Wu et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Wu et al. World Journal of Surgical Oncology 2014, 12:95
http://www.wjso.com/content/12/1/95RESEARCH Open AccessMeta-analysis on the association between
pathologic complete response and triple-negative
breast cancer after neoadjuvant chemotherapy
Kunpeng Wu1,2†, Qiaozhu Yang3†, Yi Liu4, Aibing Wu1* and Zhixiong Yang1*Abstract
Background: Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that is characterized by
poor prognosis, strong tumor invasion and a high pathologic complete response (pCR) to neoadjuvant chemotherapy
(NAC). The pCR rate is a prognostic factor for TNBC. We aimed to evaluate the relationship between pCR and TNBC
after NAC and originally tried to identify factors related to achieving pCR for TNBC using a meta-analysis.
Methods: We systematically searched the literature for pCR and breast cancer after NAC and carefully identified
eligibility criteria. The association between pCR and breast cancer subtypes was estimated using Review Manager, while
pCR rates for TNBC and non-TNBC were determined using Meta-Analyst.
Results: This analysis included a total of 9,460 cases from 27 studies. The summary odds ratio estimating the relationship
between pCR and breast cancer subtypes (TNBC vs non-TNBC) was 3.02 (95% confidence interval (CI), 2.66 to 3.42). The
TNBC pCR rate was 28.9% (95% CI, 27.0 to 30.8%) and the non-TNBC was 12.5% (95% CI, 11.7 to 13.4%). From subgroup
analyses, we identified the factors associated with the highest pCR rates for TNBC.
Conclusions: TNBC has a higher pCR rate than non-TNBC. In the NAC setting, these factors of platinum-containing, more
than six cycles, four kinds of drugs, 16 weeks’ treatment duration and sequential chemotherapy may contribute to
increasing the pCR rate.
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Triple-negative breast cancer (TNBC) is a subtype of breast
cancer that accounts for approximately 15% of all breast
cancers [1,2]. TNBC lacks the three important therapeutic
markers for clinical regimens of patients with breast cancer:
estrogen receptor (ER), progesterone receptor (PR) and hu-
man epidermal growth factor receptor 2 (HER2). Due to
the absence of a therapeutic target (endocrine therapy tar-
gets the ER and PR, and trastuzumab targets HER2), the
prognosis of patients with TNBC is poorer than that of pa-
tients with other types of breast cancer. Patients with
TNBC are characterized by early recurrence [3,4] and a sig-
nificantly shorter survival compared with those with non-
TNBCs [5,6].* Correspondence: wab801016@163.com; yangzhixiong068@126.com
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unless otherwise stated.Neoadjuvant chemotherapy (NAC) is increasingly being
used in the treatment of large operable breast cancers or
to prevent lymph node metastases, where it is as effective
as adjuvant chemotherapy and considered a standard of
treatment for patients with locally advanced breast cancer
[7]. The advantages of NAC in operable breast cancer in-
clude: increasing the rate of success of breast-conserving
surgery by downstaging the primary tumor load, early pre-
vention of cancer metastasis in lymphonodi or viscera and
providing suggestions for selecting the adjuvant chemo-
therapy regimen through estimating the clinical response
to NAC and avoiding a potentially ineffective treatment in
adjuvant chemotherapy.
Interestingly, several clinical studies on NAC for breast
cancers have shown that TNBC has lower survival and
higher relapse rates among all breast cancer subsets but
has a higher rate of pathologic complete response (pCR)
to NAC than other phenotypes and patients with pCR. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart used to identify relevant literature. ER,
estrogen receptor; pCR, pathologic complete response; PR,
progesterone receptor.
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with TNBC who do not have pCR are at increased risk
of early relapse and death [1,9]. pCR has been proven to
be a prognostic factor for breast cancer by von Min-
ckwitz and Xiangnan Kong [10,11]. Consequently, pCR
plays a very significant role in predicting prognosis and
clinical management for patients with TNBC.
We therefore performed a meta-analysis aiming to re-
port the association between NAC and pCR for TNBC.
It was also our purpose to observe which factors are po-
tentially related with pCR in TNBC treated with NAC,
such as NAC cycles, drugs and schedules.
Methods
Literature search
The MEDLINE, EMBASE and Cochrane Library data-
bases were systematically searched to September 2013.
Publications with the following search words in the title,
abstract or key words were included: breast cancer,
TNBC, NAC, preoperative chemotherapy, pathologic
complete response, pathologic complete remission and
pathologic response. The studies identified through the
search were independently screened by two authors
(KW and AW) for inclusion. Any disagreements were
arbitrated by a third author (ZY). We did not limit our
search by language, country, race or date.
Inclusion and exclusion criteria
Studies performed using humans regardless of sample size
were included if they met the following criteria: papers
studying the association between NAC and pCR in TNBCs;
all cases definitely diagnosed as breast cancer and where dis-
tant metastasis was excluded; ER, PR, HER2 measured by
immunohistochemistry (IHC) and/or fluorescence in situ
hybridization of primary cancer tissue; pCR explicitly de-
fined; and detailed statistics had to be reported (i.e. patient
numbers and percentage of pCR). Any investigations that
did not meet all inclusion criteria and cross-sectional studies
were excluded. If data were duplicated in more than one
paper, the most recent paper was included in the analysis.
Data extraction
Data were independently extracted by two authors (QY
and YL) using the same standardized table. The fields
extracted included first author, year of publication, NAC
schedule (type, number of cycles, interval and treatment
duration), and number and percentage of patients
achieving pCR in TNBC and non-TNBC. For articles
with the same population resources or overlapping data-
sets, data were extracted and reported as a single trial.
Statistical analysis
The Cochrane Collaboration Review Manager 5.1 and
Meta-Analyst Beta 3.13 statistical software were used forthis meta-analysis. The χ2 and I2 test methods were used to
evaluate the heterogeneity of the odds ratios (ORs) in the
studies. When I2 < 50% and P > 0.05 for χ2, indicating het-
erogeneity in the results, the heterogeneity in the studies
was considered acceptable and the fixed-effect model with
the Mantel–Haenszel method was used for the two-arm
meta-analysis or the inverse variance method was used for
the single-arm meta-analysis. Otherwise, a random-effect
model with the DerSimonian and Laird method was
adapted for both the one- and two-arm meta-analyses. Each
study was weighted according to the sample size.
Subgroup analyses were executed for NAC cycles, drugs
and schedules. The sensitivity was analyzed by excluding
small cases studies (defined as <100 cases) and changing
the effect model to estimate confidence. Potential publica-
tion bias was evaluated using funnel plots. An asymmetric
plot indicates there was potential publication bias; other-
wise, the plot should be shaped like a funnel.
Ethical standards
This study complies with the current laws of China.
Results
Eligible studies
We identified 516 studies in the three databases and
their bibliographies of relevant clinical trials. After ex-
cluding duplicates (n = 126), the titles and abstracts of
all remaining studies (n = 390) were reviewed. Of these
390 studies, we excluded 353 that did not meet the se-
lection criteria. After reviewing the full text of the
remaining 37 studies, we ultimately included 27 studies
[1,8,9,12-35] in the final analysis. Ten studies were ex-
cluded from the final review for these reasons: insuffi-
cient data (n = 1) [36], cross-sectional study (n = 1) [37],
distant metastasis (n = 5) [38-42], undefined pCR (n = 1)
Table 1 Characteristics of the eligible studies
Author Year Tumor stage Neoadjuvant chemotherapy TNBC pCR rate
of TNBC
non-TNBC pCR rate of
non-TNBC
OR (95% CI)
pCR no-pCR pCR no-pCR
Rouzier R [8] 2005 I, II, III 12 weeks of P followed by FAC 4 courses (weekly P (80 mg/m2) ×
12 + FAC × 4 or 3 weekly P (225 mg/m2) × 4 + FAC × 4)
10 12 45.50% 11 49 18.30% 3.71 (1.28, 10.76)
Carey LA [1] 2007 II, III A 60 mg/m2 + C 600 mg/m2 every 2 weeks or 3 weeks for 4 cycles,
either alone or as the first component of a sequential AC-taxane
neoadjuvant regimen
9 25 26.50% 8 69 10.40% 3.10 (1.08, 8.93)
Goldstein NS [12] 2007 IIA to IIIC FAC every 3 weeks × 6 FEC every 3 weeks × 6 AC every 2 weeks
(dose dense) × 4 then paclitaxel every 2 weeks (dose dense) × 4 AC
every 3 weeks × 4 then P every 1 week × 4
12 9 57.10% 16 31 34.00% 2.58 (0.90, 7.41)
Keam B [13] 2007 II, III D (75 mg/m2 or 60 mg/m2) and A (60 mg/m2 or 50 mg/m2)
by intravenous infusion every 3 weeks for 3 cycles
8 39 17.00% 3 95 3.10% 6.50 (1.64, 25.78)
Liedtke C [9] 2008 I, II, III FAC; FEC; weekly or once every 3 weeks P/D followed by FAC;
weekly or once every 3 weeks P/D followed by FEC
57 198 22.40% 98 765 11.40% 2.25 (1.56, 3.23)
Bidard FC [14] 2008 I, II, III FEC (F 500 mg/m2, E 100 mg/m2, C 500 mg/m2) or FAC
(F 500 mg/m2, A 60 mg/m2, C 500 mg/m2), every 3 weeks for 4 to 6 cycles
21 99 17.50% 7 166 4.00% 5.03 (2.06, 12.26)
Julka PK [15] 2008 IIA to IIIB 4 cycles (21 days) of Gem 1,200 mg/m2 + A 60 mg/m2,
4 cycles of Gem 1,000 mg/m2 plus Cis 70 mg/m2
7 7 50.00% 6 16 27.30% 2.67 (0.65, 10.88)
Sánchez-Muñoz A [16] 2008 II, III Schedule A: E 90 mg/m2 + C 600 mg/m2 d1 for 3 cycles followed
by a second sequence with P 150 mg/m2 + Gem 2,500 mg/m2
d1 ± trastuzumab 2 mg/kg/week according to HER2 status
Schedule B: A 40 mg/m2 d1 + P 150 mg/m2 + Gem (2,000 mg/m2)
d2, 2 weekly for 6 cycles
14 10 58.30% 17 58 22.70% 4.78 (1.80, 12.66)
Sirohi B [17] 2008 M0 F 200 mg/m2 daily with E 60 mg/m2 and Cis 60 mg/m2
both repeating 3 weekly for 6 courses
1 5 16.70% 5 49 9.30% 1.96 (0.19, 20.26)
Darb-Esfahani S [18] 2009 T2 to 3,
N0 to 2, M0
A 50 mg/m2 + D 75 mg/m2 every 14 days for 4 cycles or 4 cycles
A 60 mg/m2 plus C 600 mg/m2 every 21 days followed
by D 100 mg/m2 every 21 days for 4 cycles
8 25 24.20% 5 78 6.00% 4.99 (1.50, 16.65)
Sikov WM [19] 2009 IIA to IIIB Cb (AUG = 6) every 4 weeks and P 80 mg/m2 weekly for
16 weeks, and weekly trastuzumab was added for HER2(+) status
8 4 66.70% 16 25 39.00% 3.13 (0.81, 12.11)
Bhargava R [20] 2010 I, II, III Anthracycline-based therapy: AC, FEC; taxane-based therapy:
T/P + Cb. In many cases a sequential combination of
anthracycline and taxane was given: AC-T. The total number
of cycles ranged from 4 to 10 with an average of 6
24 55 30.40% 24 256 8.60% 4.65 (2.46, 8.80)
Chang HR [21] 2010 II, III D (75 mg/m2) and Cb (AUC = 6) were administered every 3
weeks for 4 cycles. Patients with HER2(+) tumors were randomized to
receive either additional weekly trastuzumab preoperatively or TC alone




















Table 1 Characteristics of the eligible studies (Continued)
Chavez-Macgregor M [22] 2010 M0 Taxane administered: P 175 to 250 mg/m2 on d1, 3 weekly for
4 cycles; P 80 mg/m2 weekly for 12 doses; or D 100 mg/m2 on d1,
3 weekly for 4 cycles Anthracycline regimens (3 to 6 cycles):
F 500 mg/m2, E 100 mg/m2 and C 500 mg/m2 on d1,
d3 weekly; F 500 mg/m2 on d1, d4, E 75 mg/m2 and
C 500 mg/m2 on d1, 3 weekly
95 395 19.40% 165 1419 10.40% 2.07 (1.57, 2.73)
Chen XS [23] 2010 T3 to 4,
any N, M0;any T,
N2 to 3, M0
VE: V 25 mg/m2 d1, d8 + E 60 mg/m2 d1, d3 weekly; PCb:
P 80 mg/m2 + Cb AUC = 2 d1, d8, d15, 4 weekly; CEF:
C 500 mg/m2, E 75 mg/m2 and F 500 mg/m2 d1, 3 weekly;
CTF: C 500 mg/m2, THP 50 mg/m2, and F 500 mg/m2 d1,
3 weekly; CEF➝T: D 75 mg/m2 d1, 3 weekly; ED: E
60 mg/m2 + D 75 mg/m2, 3 weekly
9 44 17.00% 19 153 11.00% 2.07 (0.86, 4.96)
Huober J [24] 2010 I, II, III 6 to 8 cycles of TAC (D 75 mg/m2, A 50 mg/m2, C 500 mg/m2
on d1, every 3 weeks) or 2 cycles of TAC followed by four
cycles of V 25 mg/m2 on d1, d8 + capecitabine 1,000 mg/m2
orally twice a day on d1 to d14 every 3 weeks
198 311 38.90% 147 820 15.20% 3.55 (2.77, 4.56)
Kim SI [25] 2010 M0 A (50 mg/m2, d1) + D (75 mg/m2, d1) chemotherapy
(AT) every 3 weeks for 3 cycles
16 60 21.10% 10 181 5.20% 4.83 (2.08, 11.21)
Pierga JY [26] 2010 II, III E (75 mg/m2) + C (750 mg/m2) intravenously every 3 weeks
for 4 cycles followed by D (100 mg/m2) every 3 weeks for
4 cycles with or without trastuzumab (8 mg/kg at first infusion
then 6 mg/kg) every 3 weeks
23 55 29.50% 14 57 19.70% 1.70 (0.80, 3.64)
Straver ME [27] 2011 T1 to 3,
N0 to 2, M0
AC (6 cycles of A 60 mg/m2 and C 600 mg/m2 every
3 weeks) or AD (6 cycles of A 50 mg/m2 and D 75 mg/m2,
every 3 weeks)
16 41 28.10% 13 181 6.70% 5.43 (2.43, 12.17)
Bernsdorf M [28] 2011 T2 to 3,
N0 to 3b, M0
4 cycles of EC (E 90 mg/m2 and C 600 mg/m2) plus
12 weeks of daily treatment with gefitinib 250 mg or
EC plus 12 weeks’ treatment with placebo. Chemotherapy
was administered every 3 weeks
12 70 14.60% 1 47 2.10% 8.06 (1.01, 64.06)
Iwata H [29] 2011 T1c to 3,
N0, M0; T1 to 3,
N1, M0
4 cycles of D (75 mg/m2) administered intravenously
every 21 days followed by 4 cycles of FEC (F 500 mg/m2,
E 100 mg/m2 and C 500 mg/m2) administered intravenously
on d1 every 21 days before surgery
14 15 48.30% 16 84 16.00% 4.90 (1.99, 12.09)
Loo CE [30] 2011 T2 to 4,
N1 to 3, M0
Either ER(+) or (–), received 6 courses of AC, administered in a
dose-dense schedule (every 2 weeks). A minority
received 6 courses of capecitabine + D or doxorubicin + D
16 41 28.10% 22 119 15.60% 2.11 (1.01, 4.40)
Medioni J [31] 2011 II, III Six 2-weekly courses of Gem 1,000 mg/m2 + D 75 mg/m2
on d1, d15 and V 25 mg/m2 + E 100 mg/m2 on d29, d43.
Patients with an objective response on d56 then received
another cycle of Gem + D on d57 and V + E on d71




















Table 1 Characteristics of the eligible studies (Continued)
Nakahara H [32] 2011 T1 to 4 HER2(–) tumors started with CE (E 75 mg/m2 × d1 + C 100
mg × daily for 14 days with 7 days’ rest) for 4 or 6 cycles.
HER2(+) tumors initiated with CE (E 90 mg/m2 × d1 or
E 50 mg/m2 × d1, d8 and C 100 mg × daily for 14 days
with 7 days’ rest)
5 13 27.80 3 65 4.40% 8.33 (1.77, 39.27)
Wu J [33] 2011 II, III P (175 mg/m2) or D (75 mg/m2) + doxorubicin (60 mg/m2)
or E (90 mg/m2) every 21 days for a total of 4 cycles
14 40 25.90 24 171 12.30% 2.49 (1.19, 5.25)
Le Tourneau C [34] 2012 II, III 4 cycles of intensified FAC (A 70 mg/m2 d1, C 700 mg/m2
d1 + d8, and F 700 mg/m2 d1 to d5) every 3 weeks
9 10 47.40 3 30 9.10% 9.00 (2.03, 39.93)
Ono M [35] 2012 II, III Anthracycline-based regimen (AC: A 60 mg/m2 + C 600 mg/m2
or CEF: C 600 mg/m2 + E 100 mg/m2 + F 600 mg/m2)
Taxane-based regimen (weekly P 80 mg/m2 or triweekly
D 75 mg/m2) Anthracycline and taxane sequentially or concurrently
(A 50 mg/m2 + D 60 mg/m2, AC or CEF followed by weekly
P or triweekly D)
26 66 28.30 9 70 11.40% 3.06 (1.34, 7.02)
A, adriamycin; C, cyclophosphamide; Cb, carboplatin; CI, confidence interval; Cis, cisplatin; d, day; D, docetaxel; E, epirubicin; F, 5-fluorouracil; Gem, gemcitabine; R2, human epidermal growth factor receptor 2; OR,
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populations were reviewed in two papers [23,45], the data
were extracted and reported as a single study. Figure 1
shows a flow diagram with the numbers of relevant studies.
Study characteristics
In all, 27 studies published between 2005 and 2012 were
included in this meta-analysis. Table 1 shows the main
characteristics of all of the studies. A total of 9,460 cases
from the 27 studies that had pathological results and
clinical data were included. Enrollment of participants
across the studies was from 1985 to 2009. Most studies
enrolled patients who had been diagnosed with breast
cancer stages II and III (n = 17), but some studies also
recruited stage I patients (n = 8) and a few studies re-
cruited non-metastatic patients (n = 3). According to
these studies, the percentage of patients achieving pCR
after NAC was 3.1 to 66.7% (TNBC, 14.6 to 66.7%; non-
TNBC, 3.1 to 39.0%). NAC consisted of an anthracycline
and/or taxane with other chemotherapeutic regimens.
Pathologic complete response and breast cancer
subtypes (triple-negative breast cancer and non-triple-
negative breast cancer)
Figure 2 shows the association between pCR and breast
cancer subtypes (TNBC and non-TNBC) after NAC. In
a fixed-effects meta-analysis of all 27 studies, TNBC has
a better pCR rate than non-TNBC (the overall summary
estimate OR was 3.02; 95% CI, 2.66 to 3.42) with noFigure 2 Forest plot of odds ratio for achieving pCR after NAC betwe
breast cancer; M-H, Mantel–Haenszel method.obvious evidence of heterogeneity (I2 = 16%, P = 0.22).
Figure 3 summarizes the percentage of patients achieving
pCR after NAC in TNBC and non-TNBC groups. In a
single-group fixed-effects meta-analysis of all 27 studies,
the overall summary estimated pCR rate was 28.9% (95%
CI, 27.0 to 30.8%) in TNBC and 12.5% (95% CI, 11.7 to
13.4%) in non-TNBC. There was no obvious evidence of
heterogeneity (I2 = 44.1% and I2 = 43.8%, respectively).
The subgroup analysis outcomes are shown in Table 2.
The initially planned subgroup of chemotherapy inter-
mission was not used due to a lack of similar data in
these studies. Instead, we used subgroups for NAC treat-
ment duration, which was defined as the period of time
that patients were treated with NAC. These subgroup
analyses involve treatment cycle (<4 cycles, 4 cycles,
6 cycles or >6 cycles), types of chemotherapy regi-
men (anthracycline-based, taxane-containing, platinum-
containing, gemcitabine-containing), the number of
chemotherapy drugs (two kinds of drugs, three kinds of
drugs or four kinds of drugs), treatment duration
(<12 weeks, 12 weeks, 16 weeks or >16 weeks) and
chemotherapy schedule (conventional vs sequential chemo-
therapy). We discovered that the pCR rate was higher with
TNBC than with non-TNBC for all subgroups. A single-
group meta-analysis of all 27 studies [1,8,9,12-35] identified
the subgroups (four kinds of chemotherapy drugs, >6 cycles,
platinum-containing chemotherapy, 16 weeks’ treatment
duration, sequential chemotherapy) with the highest pCR
rate for both TNBC and non-TNBC patients.en TNBC and non-TNBC. CI, confidence interval; TNBC, triple-negative
Figure 3 Forest plots of pooled percentage of achieving pCR after NAC for TNBC and non-TNBC groups. TNBC, triple-negative breast cancer.
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studies and changing the effect model had little effect on
estimated OR and pCR rate and did not change the
strength of the association between NAC and pCR for
TNBC and non-TNBC. The ORs were 3.13 (95% CI,
2.66 to 3.68) for excluding small cases studies and 2.92
(95% CI, 2.56 to 3.34) for changing the effect model. For
TNBC patients, the odds of pCR were 27.2% (95% CI,
25.3 to 29.2%) for excluding small cases studies and
30.5% (95% CI, 25.9 to 35.5%) for changing the effect
model. For non-TNBC patients, the odds of pCR were
11.5% (95% CI, 10.7 to 12.5%) for excluding small case
studies and 12.5% (95% CI, 10.4 to 14.9%) for changing
the effect model. Funnel plots were generated to test for
potential publication bias (Figures 4 and 5). Potential
publication biases were found in these funnel plots.
Discussion
TNBC is a subtype of breast cancer that has particular
biological features such as high pathologic grade, poor
prognosis, short survival, strong tumor invasion, and ahigh incidence of local relapse and distant metastasis
[46]. In addition, a high pCR rate after NAC is also a sig-
nificant characteristic of TNBC, and pCR has been
proved to be a typical marker predictive of clinical re-
sponse and survival in TNBC patients [11,47]; however,
diverse pCR rates have been reported in various studies.
In this meta-analysis of 27 studies containing 9,460
cases, pCR rates were 28.9% (95% CI, 27.0 to 30.8%) for
2,952 cases of TNBC and 12.5% (95% CI, 11.7 to 13.4%)
for 6,508 cases of non-TNBC. Patients with TNBC have
a higher probability of achieving pCR than those with
non-TNBC (OR, 3.02; 95% CI, 2.66 to 3.42); that is, the
TNBC pCR rate is about two times that of non-TNBC
and TNBC exhibits a better response to NAC than non-
TNBC.
With the rapid development of molecular and genetic
diagnosis techniques, the heterogeneity of breast cancer
has been discovered. Based on the analysis of RNA ex-
pression profiles, four distinct molecular subtypes of
breast cancer (luminal subgroup, basal-like subgroup,
HER2 subgroup and normal-like breast tumors) were
Table 2 Subgroup analyses of various factors related to achieving pathologic complete response
Category Number of studies
(references)
Summary estimate
odds ratio (95% CI)
Heterogeneity,
I2 (%)










<4 cycles 2 [13,25] 5.27 (2.57, 10.79) 0 19.6 (13.5, 27.6) 0 4.6 (2.7, 7.8) 0
4 cycles 6 [15,21,28,
33,34,45]
3.51 (2.21, 5.57) 0 29.2 (23.0, 26.3) 41.4 15.0 (11.8, 18.8) 35.1
6 cycles 3 [17,27,30] 3.10 (1.84, 5.22) 35 27.6 (20.3, 36.3) 0 11.0 (8.2, 14.7) 41.3
>6 cycles 3 [8,26,29] 2.77 (1.66, 4.61) 41 36.8 (28.8, 45.6) 33.8 17.8 (13.4, 23.3) 0
Types of NAC regimen
Anthracycline-based 19 [1,8,9,12-14,
16-18,25-34]
3.19 (2.63, 3.88) 7 26.8 (24.1, 29.6) 39.8 12.1 (10.8, 13.5) 43.2
Taxane-containing 10 [8,13,18,19,21,25,
26,29,33,45]
3.29 (2.41, 4.48) 0 30.5 (25.9, 35.5) 38.2 14.9 (12.6, 17.5) 44.8
Platinum-containing 4 [17,19,21,45] 3.10 (1.59, 6.03) 0 44.2 (30.8, 58.5) 31.1 21.3 (16.3, 27.3) 43.6
Gemcitabine-containing 2 [15,31] 3.49 (1.42, 8.57) 0 44.5 (29.3, 60.8) 0 18.8 (11.2, 29.8) 30.2
The number of drug in NAC
Two kinds of drugs 9 [13,15,19,21,25,
27,32,33,45]
3.89 (2.75, 5.49) 0 28.7 (23.8, 34.2) 36.3 12.9 (10.7, 15.5) 46.1
Three kinds of drugs 4 [14,17,26,34] 2.39 (1.77, 3.23) 16 22.5 (18.8, 26.5) 19.8 11.2 (9.5, 13.3) 43.6
Four kinds of drugs 4 [8,9,29,31] 4.83 (2.80, 8.35) 0 45.7 (35.8, 55.9) 0 15.5 (11.4, 20.6) 0
Total treatment duration of NAC
<12 weeks 2 [13,25] 5.27 (2.57, 10.79) 0 19.6 (13.5, 27.6) 35.4 4.6 (2.7, 7.8) 0
12 weeks 7 [14,15,21,28,
30,33,34]
3.42 (2.34, 4.99) 0 24.9 (20.5, 29.9) 42 13.3 (10.7, 16.3) 42.6
16 weeks 2 [19,45] 2.88 (1.27, 6.56) 0 44.2 (28.4, 61.3) 41.4 24.8 (17.7, 33.7) 46.7
>16 weeks 6 [8,17,24,26,
27,29]
3.47 (2.80, 4.30) 7 37.6 (34.0, 41.2) 25.8 14.7 (12.9, 16.6) 38
NAC schedules
Conventional chemotherapy 8 [13-15,17,21,
25,27,45]
4.40 (3.02, 6.42) 0 24.1 (19.8, 29.0) 35.6 9.7 (7.7, 12.1) 44.5
Sequential chemotherapy 4 [8,26,29,31] 2.96 (1.85, 4.72) 20 37.4 (30.0, 45.5) 22.5 17.2 (13.2, 22.1) 0
CI, confidence interval; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response; TNBC, triple-negative breast cancer.
Figure 4 Funnel plot for identifying publication bias in the relationship for achieving pCR between TNBC and non-TNBC. OR, odds ratio.
Wu et al. World Journal of Surgical Oncology 2014, 12:95 Page 8 of 12
http://www.wjso.com/content/12/1/95
Figure 5 Funnel plot for identifying publication bias for the pooled pCR rates in TNBC and non-TNBC. TNBC, triple-negative breast cancer.
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like breast cancer is IHC characterized by overexpres-
sion of cytokeratin 5/6/14 and epidermal growth factor
receptor and lack of expression of ER, PR and HER2
[49,50]. There is intrinsic homology but incomplete
overlap between IHC-defined TNBC and molecular-
defined basal-like breast cancer. Nearly 80% of TNBC
cases have a basal-like molecular profile [51,52]. In
addition to the basal-like profile, TNBC encompasses
other molecular subtypes, particularly normal-like and
claudin-low [53]. In this meta-analysis, we found four
studies of participants with basal-like breast cancer and
an estimated pCR rate of 42.5% (95% CI, 32.4 to 53.2%).
There was no obvious evidence of heterogeneity (I2 =
31.2%). Basal-like breast cancer has a higher pCR rate
than TNBC. Thus, there is evidence that the subtype of
triple-negative cancers is heterogeneous and we cannot
simply consider them a single group.
Both anthracyclines and taxanes are usually used in the
neoadjuvant treatment of breast cancer, and patients re-
spond well to them. Of the 27 studies in this meta-analysis,
19 used anthracycline-based NAC and 11 used taxane-
containing regimens. The pCR rates for TNBC were 26.8%
(95% CI, 24.1 to 29.6%) for the anthracycline-based group
and 30.5% (95% CI, 25.9 to 35.5%) for the taxane-
containing group, a non-significant difference. Interestingly,
the platinum-containing group had a higher pCR rate than
either the anthracycline-based or taxane-containing groups.
It is believed that most TNBC cells are expected to have a
BRCA1 mutation or absence [54,55], which is useful for the
treatment of TNBC since loss of BRCA1 function in TNBC
is related to the sensitivity of DNA-damaging chemother-
apy agents (platinum, alkylating agents, etc.) and may also
be related to the resistance of spindle poisons (taxanes and
vinblastines) [56]. TNBC is strongly related to germ-line
mutations in the BRCA1 gene, and 90% of BRCA1-mutatedcancers are TNBC [57]. Some researchers have demon-
strated that the addition of platinum agents to anthracy-
cline and/or taxane regimens in NAC has promise for
outcomes [58]. Although the gemcitabine-containing group
included two studies with 108 cases [15,31], we should not
ignore this group, which achieved the highest pCR rate.
Due to lack of sufficient cases to support gemcitabine
use in NAC for TNBC, more clinical trials should be
implemented.
A hypothesis-generating study indicated that TNBC/
basal-like breast cancer had a poorer response to
anthracycline-based therapy compared with other breast
cancer subtypes [59]. The results of this study were laterally
validated through this meta-analysis, which indicated that
the anthracycline-based group had the lowest pCR. Al-
though some new drugs have been used in NAC for TNBC
(such as EGFR inhibitors (NCT00491816), epothilones
(NCT01097642) and ixabepilone (NCT01097642)), the
platinum-containing strategy was still the first choice in
most clinical trials of TNBC and NAC (NCT00887575,
NCT01194869 and NCT00813956). It is a pity that the
final reports of these clinical trials have not been submitted;
however, these reports were very valuable for providing in-
formative references for the clinical practice. Based on the
platinum-containing subgroup analysis of 292 cases from 4
studies [17,19,21,45] and some cell biology research
[54-57], we recommend the platinum-containing strategy
should be used in NAC for TNBC.
From the subgroup analyses of cycles, drug types, treat-
ment duration and chemotherapy schedules (Table 2), we
observed that groups of more than six cycles, four kinds of
drugs, 16 weeks treatment duration and sequential
chemotherapy obtained the highest pCR rate in the re-
spective subgroups for TNBC (36.8%: 95% CI, 28.8 to
45.6%; 45.7%: 95% CI, 35.8 to 55.9%; 37.6%: 95% CI, 34.0
to 41.2%; 37.4%: 95% CI, 30.0 to 45.5%, respectively). We
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TEC had greater weight in the subgroups for four kinds of
drugs [8,9,29] and sequential chemotherapy for TNBC
[8,26,29] (the weight was 76.6% and 84.5%, respectively).
This chemotherapy scheme may be a good choice of NAC
for TNBC.
Three meta-analyses were published recently on breast
cancer and pCR. Von Minckwitz et al. [11] presented a
meta-analysis of 6,377 operable and non-metastatic
breast cancer patients, who received neoadjuvant anthra-
cyclines or taxanes. They discerned various definitions
of pCR and evaluated the prognostic impact of pCR on
disease-free survival and overall survival in various
breast cancer subgroups. The authors concluded that
pCR should be conservatively defined as ypT0 ypN0 ex-
cluding ductal carcinoma in situ and that pCR is an ef-
fective mark of survival for TNBC, luminal B and non-
luminal (HER2-positive). Kong et al. [10] completed a
meta-analysis that included 16 studies with 3,776 patients
with breast cancer to determine whether pathologic re-
sponse after NAC predicts outcomes. The authors con-
cluded that the pathologic response is prognostic for
relapse-free survival, disease-free survival and overall sur-
vival. Houssami et al. [60] reported a meta-analysis with
two analysis models to provide evidence of the association
between various factors for breast cancer and the rates of
achieving pCR. Our meta-analysis included 27 studies
with 9,460 non-metastatic breast cancer patients, and we
aimed to evaluate the association between pCR and breast
cancer subtypes (TNBC and non-TNBC) after NAC, and
originally tried to identify factors related to achieving pCR
for TNBC.
There are some potential limitations in this meta-
analysis. Hormone receptor assessment varies across dif-
ferent studies, and different IHC standards are used to
define positivity. Most studies define ER/PR-negative
IHC using the threshold of <10% immunoreactive cells.
The American Society of Clinical Oncology and the Col-
lege of American Pathologists guidelines for IHC dictate
that a threshold of <1% of cells should be used to define
ER/PR-negative so that more patients with breast cancer
will receive endocrine therapy [53,61]. Moreover, it is
unfortunate that sufficient detailed survival data for per-
forming survival analysis are lacking.
Conclusions
In summary, this meta-analysis provides strong evidence
that TNBC has a higher pCR rate than non-TNBC. In
the NAC setting, these factors of platinum-containing,
more than six cycles, four kinds of drugs, 16 weeks’
treatment duration and sequential chemotherapy may
result in a higher pCR rate. This information provides
valuable direction for clinicians performing relevant clin-
ical studies in the future.Abbreviations
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